Department of Radiation Oncology, Columbia University Irving Medical Center, 622 West 168th Street, BNH B-11, New York, NY, 10032, USA.
Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, 10032, USA.
J Neurooncol. 2019 May;143(1):145-155. doi: 10.1007/s11060-019-03149-4. Epub 2019 Mar 14.
Non-small cell lung cancer (NSCLC) brain metastases are associated with substantial morbidity and mortality. During recent years, accompanying dramatic improvements in systemic disease control, NSCLC brain metastases have emerged as an increasingly relevant clinical problem. However, optimal surveillance practices remain poorly defined. This purpose of this study was to further characterize the natural history, clinical course and risk factors associated with earlier development of subsequent NSCLC brain metastases to better inform clinical practice and help guide survivorship care.
We retrospectively reviewed all institutional NSCLC brain metastasis cases treated with radiotherapy between 1997 and 2015. Exclusion criteria included presence of brain metastases at initial NSCLC diagnosis and incomplete staging information. Interval time to brain metastases and subsequent survival were characterized using Kaplan-Meier and multivariate Cox regression analyses.
Among 105 patients within this cohort, median interval time to development of brain metastases was 16 months. Median interval times were 29, 19, 16 and 13 months for Stage I-IV patients, respectively (P = 0.016). Additional independent predictors for earlier development of NSCLC brain metastases included non-adenocarcinomatous histopathology (HR 3.036, P < 0.001), no prior surgical resection (HR 1.609, P = 0.036) and no prior systemic therapy (HR 3.560, P = 0.004). Median survival following intracranial progression was 16 months. Delayed development of brain metastases was associated with better prognosis (HR 0.970, P < 0.001) but not survival following intracranial disease onset.
Collectively, our results provide valuable insights into the natural history of NSCLC brain metastases. NSCLC stage, histology, prior surgical resection and prior systemic therapy emerged as independent predictors for interval time to brain metastases.
非小细胞肺癌(NSCLC)脑转移与较高的发病率和死亡率密切相关。近年来,随着全身疾病控制水平的显著提高,NSCLC 脑转移已成为一个日益突出的临床问题。然而,最佳监测实践仍未得到明确界定。本研究的目的是进一步描述与 NSCLC 脑转移早期发生相关的自然史、临床病程和危险因素,以便更好地为临床实践提供信息,并有助于指导生存护理。
我们回顾性分析了 1997 年至 2015 年间在我院接受放疗的所有 NSCLC 脑转移病例。排除标准包括初始 NSCLC 诊断时存在脑转移和不完全分期信息。采用 Kaplan-Meier 和多变量 Cox 回归分析描述脑转移的时间间隔和随后的生存情况。
在该队列的 105 例患者中,脑转移的中位时间间隔为 16 个月。Ⅰ期-Ⅳ期患者的中位时间间隔分别为 29、19、16 和 13 个月(P=0.016)。NSCLC 脑转移更早发生的其他独立预测因素包括非腺癌组织病理学(HR 3.036,P<0.001)、无先前手术切除(HR 1.609,P=0.036)和无先前全身治疗(HR 3.560,P=0.004)。颅内进展后中位生存时间为 16 个月。脑转移延迟发生与预后较好相关(HR 0.970,P<0.001),但与颅内疾病发生后的生存无关。
总之,我们的研究结果为 NSCLC 脑转移的自然史提供了有价值的见解。NSCLC 分期、组织学、先前手术切除和先前全身治疗是脑转移时间间隔的独立预测因素。